Table 2.
Baseline Characteristics According to sST2 Level, Overall and by STEMI/NSTEMI Presentation
| Characteristic | Overall | STEMI | NSTEMI | |||
|---|---|---|---|---|---|---|
| Normal sST2 (n=682) | High sST2 (n=719) | Normal sST2 (n=148) | High sST2 (n=143) | Normal sST2 (n=534) | High sST2 (n=576) | |
| sST2, median (25th–75th percentile), ng/mL | 32.2 (25.2–39.1) | 99.5 (62.0–200.0)a | 32.1 (24.8–41.2) | 88.2 (60.9–200.0)a | 32.3 (25.2–38.6) | 102.4 (62.5–199.8)a |
| Age, mean (SD), y | 64.6 (13.8) | 69.9 (15.5)a | 59.8 (14.0) | 63.8 (17.3)b | 65.9 (13.5) | 71.4 (14.7)a |
| Male sex, n (%) | 491 (72) | 362 (50)a | 120 (81) | 89 (62)a | 371 (70) | 273 (47)a |
| Smoking, n (%) | ||||||
| Never | 265 (39) | 294 (41) | 60 (41) | 64 (45) | 205 (38) | 230 (40) |
| Former | 270 (40) | 292 (41) | 47 (32) | 44 (31) | 223 (42) | 248 (43) |
| Current | 147 (22) | 133 (19) | 41 (28) | 35 (24) | 106 (20) | 98 (17) |
| BMI, n (%) | ||||||
| <18.5 kg/m2 (underweight) | 6 (1) | 30 (4)a | 2 (1) | 4 (3) | 4 (1) | 26 (5)a |
| 18.5–24.9 kg/m2 (normal weight) | 130 (19) | 210 (29) | 30 (20) | 35 (24) | 101 (19) | 175 (30) |
| 25.0–29.9 kg/m2 (overweight) | 281 (41) | 232 (32) | 66 (45) | 53 (37) | 215 (40) | 179 (31) |
| ≥30.0 kg/m2 (obese) | 264 (39) | 246 (34) | 50 (34) | 51 (36) | 214 (40) | 195 (34) |
| Family history of CAD, n (%) | 175 (26) | 114 (16)a | 43 (29) | 26 (18)b | 132 (25) | 88 (15)a |
| Hypertension, n (%) | 461 (68) | 532 (74)a | 85 (57) | 83 (58) | 376 (70) | 449 (78)a |
| Hyperlipidemia, n (%) | 460 (67) | 465 (65) | 92 (62) | 84 (59) | 368 (69) | 381 (66) |
| Diabetes mellitus, n (%) | 135 (20) | 199 (28)a | 20 (14) | 38 (27)a | 115 (22) | 161 (28)b |
| History of HF, n (%) | 42 (6) | 137 (19)a | 4 (3) | 14 (10)a | 38 (7) | 123 (21)a |
| History of CAD, n (%) | 87 (13) | 145 (20)a | 14 (10) | 10 (7) | 73 (14) | 135 (23)a |
| Maximum troponin T, median (25th–75th percentile), ng/mL | 0.60 (0.21–1.65) | 0.67 (0.18–2.61) | 1.76 (0.69–3.80) | 3.11 (0.95–6.63)a | 0.41 (0.17–1.19) | 0.42 (0.14–1.52) |
| Killip class >1, n (%) | 81 (12) | 234 (33)a | 26 (18) | 44 (31)b | 55 (10) | 190 (34)a |
| STEMI, n (%) | 148 (22) | 143 (20) | ··· | ··· | ··· | ··· |
| Anterior MI, n (%) | 185 (27) | 317 (44)a | 81 (55) | 94 (66) | 104 (20) | 223 (39)a |
| Reperfusion/revascularization during hospitalization, n (%) | 484 (71) | 317 (44)a | 120 (81) | 104 (73) | 364 (68) | 213 (37)a |
| Charlson index, n (%) | ||||||
| 0 | 320 (47) | 182 (25)a | 78 (53) | 53 (37)a | 242 (45) | 129 (22)a |
| 1–2 | 203 (30) | 245 (34) | 52 (35) | 48 (34) | 151 (28) | 197 (34) |
| ≥3 | 159 (23) | 292 (41) | 18 (12) | 42 (29) | 141 (26) | 250 (43) |
| eGFR, median (25th–75th percentile), mL/min per 1.73 m2 | 63.9 (53.9–76.5) | 57.2 (43.9–71.2)a | 69.0 (59.9–82.2) | 61.8 (47.7–70.9)a | 62.6 (52.7–75.6) | 56.2 (42.4–71.2)a |
| GRACE score, median (25th–75th percentile) | 112 (92–133) | 136 (104–160)a | 99 (81–121) | 109 (81–145)a | 117 (96–135) | 140 (114–162)a |
| TIMI score, median (25th–75th percentile) | 3 (2–4) | 3 (2–5)a | 3 (2–5) | 4 (2–7)a | 3 (2–4) | 3 (2–4) |
| Medication at discharge, n (%) | ||||||
| Aspirin | 627 (92.1) | 521 (78.9)a | 142 (95.9) | 123 (94.6) | 485 (91.0) | 398 (75.1)a |
| Statins | 596 (87.5) | 457 (69.2)a | 137 (92.6) | 114 (87.7) | 459 (86.1) | 343 (64.7)a |
| β Blockers | 608 (89.3) | 533 (80.8)a | 141 (95.3) | 112 (86.2)a | 467 (87.6) | 421 (79.4)a |
| ACE/ARB | 414 (60.8) | 394 (59.7) | 101 (68.2) | 101 (77.7) | 313 (58.7) | 293 (55.3) |
ACE indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; GRACE, Global Registry of Acute Coronary Events; HF, heart failure; MI, myocardial infarction; NSTEMI, non–ST‐elevation MI; sST2, soluble suppression of tumorigenicity‐2; STEMI, ST‐elevation MI; and TIMI, Thrombolysis in Myocardial Infarction.
a
P≤0.01.
b
P≤0.05.